News
Can Marijuana Reduce Opioid Dependance?
The Washington Post has reported on the variable laws, views and use of marijuana in treating pain.
Currently 1.4 million patients in 28 states use legal medical marijuana for a variety of medical conditions - chronic pain being one.
High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
Despite recent advances in treatment of rheumatoid arthritis (RA), MANY patients on existent biological therapy fail to achieve remission. Therapies with novel mechanisms of actions, great efficacy and well balanced safety profile remain an unmet need.
The RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Higher Hip and Knee Replacement Revision Rates in Younger Patients
Joint arthroplasty has grown into a billion dollar industry worldwide. However, optimal timing and the success of total joint replacements in younger patient groups has not been well studied.
Sirukumab Effective in Rheumatoid Arthritis
Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 (IL-6) and is being developed for use in rheumatoid arthritis (RA) and other inflammatory diseases.
DMARD Switching in Psoriatic Arthritis
Switching biologic disease-modifying anti-rheumatic drug (bDMARD) therapy after failure of a first bDMARD for the treatment of psoriatic arthritis (PsA) can be effective, according to a review of the literature and PsA consensus treatment recommendations.
Quarter of Patients Claim Diet Influences Their Rheumatoid Arthritis
Patients often characterize certain foods as “inflammatory” or “anti-inflammatory” as they combat their arthritis.
Drugs Contribute to Infectious Risks in Lupus
Multiple patient- and disease-related factors -- including medication use -- were associated with the development of severe infections among patients with systemic lupus erythematosus, a Spanish study found.
Abatacept Efficacy Giant Cell Arteritis
This appears to be the year for biologic treatments in giant cell artertis (GCA).
Biosimilar Reports – February 2017
Biosimilar reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists. Many of these items were compiled from news sources, journal articles and regulatory documents and are cited and linked within each section.
The RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA). Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.
Top Ten Things Rheumatologists Should Know When Ordering Imaging
As a musculoskeletal radiologist, I work every day with rheumatologists. I have been in practice for approximately 17 years and had a musculoskeletal radiology fellowship prior to establishing my practice.
Valeants Brodalumab FDA Approved for Psoriasis
FDA has approvesd the IL-17 targeted therapy Siliq (brodalumab) for moderate-severe plaque psoriasis.
